Yes, the same drug they mocked as “horse paste” is now being seriously studied—for its ability to kill cancer cells.
On February 10, the NIH confirmed it’s funding preclinical trials on ivermectin’s anti-cancer properties. Dr. Anthony Letai, head of the National Cancer Institute, said there’s “enough interest” and “enough reports” to take it seriously. Studies are already underway, with results expected in just a few months.
This follows 2024 and 2025 reviews by U.S. scientists showing signs that ivermectin can inhibit tumors. The NIH is now backing that research, pointing to ivermectin’s Nobel Prize-winning legacy and its decades of safe, FDA-approved use in humans.
But instead of welcoming a promising, low-cost treatment, the media doubled down. Outlets like MedPage Today rushed to dismiss the story as “right-wing hype,” ignoring the science and smearing anyone who dared to ask questions.
Why attack a drug that could save lives—unless the real threat is to their bottom line?
If ivermectin works, it won’t just save lives. It’ll shatter the system built to suppress it.
